# VERTEX PHARMACEUTICALS INC / MA (VRTX) — capital_return/buyback_authorization [pending]
Source: SEC API (secapi.ai) · situation sit_3c8927a8a0ee2f13c573 · retrieved 2026-08-11T16:13:53.992Z

## Overview
Vertex Pharmaceuticals is a global biotechnology company that develops transformative medicines for serious diseases, with approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain, and a robust clinical pipeline in nephrology, neuropathic pain, diabetes, and other serious diseases.

Vertex Pharmaceuticals entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions. Upon completion, Crinetics will add rare endocrine diseases as Vertex's fifth pillar, further diversifying its portfolio.

## Terms
- Counterparty: Crinetics Pharmaceuticals · Deal value: $10.00B · Consideration: cash · Price/share: $85

## Key dates
- Announced 2026-08-03

## Timeline
- 2026-08-03 · 8-K (0000875320-26-000256): 8-K - VERTEX PHARMACEUTICALS INC / MA — *Vertex Pharmaceuticals is a global biotechnology company that develops transformative medicines for serious diseases, with approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain, and a robust clinical pipeline in nephrology, neuropathic pain, diabetes, and other serious diseases.* Vertex Pharmaceuticals entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions. Upon completion, Crinetics will add rare endocrine diseases as Vertex's fifth pillar, further diversifying its portfolio.
  https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000256.txt

## Citations
- 0000875320-26-000256 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000087532026000256